RT Journal Article
SR Electronic
T1 Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20164285
DO 10.1101/2020.07.29.20164285
A1 Xiangyu Chen
A1 Zhiwei Pan
A1 Shuai Yue
A1 Fei Yu
A1 Junsong Zhang
A1 Yang Yang
A1 Ren Li
A1 Bingfeng Liu
A1 Xiaofan Yang
A1 Leiqiong Gao
A1 Zhirong Li
A1 Yao Lin
A1 Qizhao Huang
A1 Lifan Xu
A1 Jianfang Tang
A1 Li Hu
A1 Jing Zhao
A1 Pinghuang Liu
A1 Guozhong Zhang
A1 Yaokai Chen
A1 Kai Deng
A1 Lilin Ye
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.29.20164285.abstract
AB COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Science and Technology Major Project (No. 2017ZX10202102-006-002 to L.Y.), the National Natural Science Fund for Distinguished Young Scholars (No. 31825011 to L.Y.) and the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control (No. cstc2020jscx-2 to L.Y.; No. cstc2020jscx-fyzx0074 to Y.C.; cstc2020jscx-fyzx0135 to Y.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received IRB approvals at Guangzhou Eighth People Hospital (KE202001134) and Chongqing Public Health Medical Center (2020-023-01-KY).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are no additional data in the study.